Nkarta: Pushing Deeper Into a Discount Versus Their Holdings, for No Real Reason

Nkarta, Inc. (NASDAQ: NKTX) is increasingly trading at a steep discount to the value of its holdings — and yet, according to analyst Galzus Research, there appears to be no substantive new setback to justify that valuation gap. Galzus Research argues that Nkarta’s pivot toward autoimmune indications — powered by its lead allogeneic CAR‑NK candidate NKX019 — remains compelling, and the company holds sufficient cash to support over three years of operational runway. The article highlights that despite this positive pipeline trajectory, and a strong cash cushion, the market appears to apply a heavy discount to the enterprise. Clinical data is expected in the first half of 2026, which Galzus acknowledges is a risk factor, but argues the present valuation may be overly conservative. In essence: Nkarta’s fundamentals haven’t materially changed to warrant the drop in valuation; the discount may be driven more by sentiment than by concrete operational shortfalls. For investors tracking the biotech cell‑therapy space, the mismatch between potential and market pricing may signal an opportunity — though not without the usual clinical‑stage risk. #Nkarta #CARNK #biotechvaluation #celltherapy #SlimScan #GrowthStocks #CANSLIM